Breaking News

Enveric Biosciences Relocates HQ to Cambridge, MA

This helps leverage the Greater Boston biotech hub’s scientific and financial ecosystem and advance EB-003 into a first-in-human trial in 2026.

By: Rachel Klemovitch

Assistant Editor

Enveric Biosciences, a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, announced the relocation of its corporate headquarters to Cambridge, Massachusetts. Enveric believes the move will foster stronger collaborations, facilitate recruitment, and enhance visibility within a vibrant life sciences cluster and a dynamic investor community. This move will also advance the company’s EB-003 molecule. EB-003 is des...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters